Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

434
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
434
Pericarditis II: Clinical Features and Diagnostic Tests01:19

Pericarditis II: Clinical Features and Diagnostic Tests

212
Pericarditis is distinguished by inflammation of the pericardium, the fibrous sac that encases the heart. It can be acute, lasting less than six weeks, or chronic, persisting for over three months. Understanding its clinical manifestations and diagnostic findings is crucial for timely and effective management.Clinical ManifestationsWhile pericarditis can be asymptomatic, it usually presents with characteristic symptoms such as:Chest Pain: The most characteristic symptom of pericarditis is chest...
212
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

696
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
696
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

334
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
334
Psychoneuroimmunology: Cardiovascular Disease01:27

Psychoneuroimmunology: Cardiovascular Disease

270
Psychoneuroimmunology (PNI) is a multidisciplinary field that examines how psychological factors, particularly stress, interact with the immune system and impact physical health. Research in PNI has shown that chronic or traumatic stress can disrupt both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. These disruptions contribute to serious health conditions, including cardiovascular diseases.
A key area of focus in PNI is the relationship between stress and coronary...
270
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

115
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
115

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Stratified polymer brushes from microcontact printing of polydopamine initiator on polymer brush surfaces.

Macromolecular rapid communications·2014
Same author

Distinct morphological features of ruptured culprit plaque for acute coronary events compared to those with silent rupture and thin-cap fibroatheroma: a combined optical coherence tomography and intravascular ultrasound study.

Journal of the American College of Cardiology·2014
Same author

The ABI4-induced Arabidopsis ANAC060 transcription factor attenuates ABA signaling and renders seedlings sugar insensitive when present in the nucleus.

PLoS genetics·2014
Same author

Evaluation of global longitudinal strain of left ventricle and regional longitudinal strain in the region of left ventricular leads predicts the response to cardiac resynchronization therapy in patients with ischemic heart failure.

Cell biochemistry and biophysics·2014
Same author

Exosomes derived from mesenchymal stem cells.

International journal of molecular sciences·2014
Same author

Association of apolipoprotein E polymorphism with maximal oxygen uptake after exercise training: a study of Chinese young adult.

Lipids in health and disease·2014

Related Experiment Video

Updated: Dec 20, 2025

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

5.7K

C-Reactive Protein Level May Predict the Risk of COVID-19 Aggravation.

Guyi Wang1, Chenfang Wu1, Quan Zhang2

  • 1Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, China.

Open Forum Infectious Diseases
|May 27, 2020
PubMed
Summary

C-reactive protein (CRP) can predict COVID-19 severity. In mild cases, a CRP level of 26.9 mg/L or higher suggests a higher risk of disease aggravation, aiding early clinical intervention.

Keywords:
C-reactive proteinCOVID-19biomarkers

More Related Videos

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
06:37

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety

Published on: September 15, 2023

965
Detection and Quantification of Calcitonin Gene-Related Peptide CGRP in Human Plasma Using a Modified Enzyme-Linked Immunosorbent Assay
07:14

Detection and Quantification of Calcitonin Gene-Related Peptide CGRP in Human Plasma Using a Modified Enzyme-Linked Immunosorbent Assay

Published on: June 16, 2023

3.1K

Related Experiment Videos

Last Updated: Dec 20, 2025

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

5.7K
Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
06:37

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety

Published on: September 15, 2023

965
Detection and Quantification of Calcitonin Gene-Related Peptide CGRP in Human Plasma Using a Modified Enzyme-Linked Immunosorbent Assay
07:14

Detection and Quantification of Calcitonin Gene-Related Peptide CGRP in Human Plasma Using a Modified Enzyme-Linked Immunosorbent Assay

Published on: June 16, 2023

3.1K

Area of Science:

  • Infectious Diseases
  • Clinical Medicine
  • Biomarkers

Background:

  • A subset of coronavirus disease 2019 (COVID-19) patients initially presenting with mild symptoms may progress to severe disease.
  • Distinguishing these patients early is clinically challenging.
  • Understanding clinical characteristics and predictive markers for disease aggravation is crucial.

Purpose of the Study:

  • To describe clinical characteristics of nonsevere COVID-19 patients who progressed to severe cases.
  • To analyze factors associated with disease aggravation.
  • To explore C-reactive protein (CRP) as a predictive marker for COVID-19 severity.

Main Methods:

  • Retrospective analysis of clinical and laboratory data from nonsevere adult COVID-19 patients.
  • Logistic regression modeling to identify factors associated with disease aggravation.
  • Receiver operating characteristic (ROC) curve analysis to evaluate the prognostic ability of CRP.

Main Results:

  • Approximately 7.7% of nonsevere COVID-19 patients progressed to severe cases.
  • Aggravated patients exhibited significantly higher C-reactive protein (CRP) levels compared to nonsevere patients (median 43.8 mg/L vs 12.1 mg/L).
  • Regression analysis confirmed CRP's significant association with aggravation, with an AUC of 0.844 and an optimal threshold of 26.9 mg/L.

Conclusions:

  • C-reactive protein (CRP) is a valuable marker for anticipating the potential aggravation of nonsevere COVID-19.
  • An optimal CRP threshold of 26.9 mg/L can help identify patients at higher risk.
  • Early identification facilitates timely clinical intervention for severe COVID-19.